Insider Selling: Artivion, Inc. (NYSE:AORT) SVP Sells 472 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 472 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.29, for a total value of $11,936.88. Following the completion of the transaction, the senior vice president now owns 172,743 shares in the company, valued at approximately $4,368,670.47. The trade was a 0.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Artivion Stock Performance

Shares of Artivion stock opened at $24.78 on Friday. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -1,239.05 and a beta of 1.79. The firm’s fifty day simple moving average is $29.23 and its 200-day simple moving average is $27.80. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion, Inc. has a 12 month low of $19.11 and a 12 month high of $32.33.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. As a group, equities analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AORT. Oppenheimer upped their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Needham & Company LLC dropped their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Stifel Nicolaus cut their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Finally, JMP Securities restated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion has an average rating of “Buy” and a consensus target price of $31.40.

Hedge Funds Weigh In On Artivion

Several institutional investors and hedge funds have recently added to or reduced their stakes in AORT. Wellington Management Group LLP boosted its stake in shares of Artivion by 2.9% in the third quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock valued at $44,090,000 after buying an additional 46,267 shares in the last quarter. Wasatch Advisors LP boosted its stake in shares of Artivion by 27.7% during the 4th quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock worth $29,791,000 after acquiring an additional 226,160 shares in the last quarter. Next Century Growth Investors LLC increased its stake in Artivion by 29.7% in the 4th quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company’s stock valued at $14,085,000 after purchasing an additional 112,918 shares in the last quarter. Northern Trust Corp grew its holdings in Artivion by 10.0% in the fourth quarter. Northern Trust Corp now owns 463,250 shares of the company’s stock valued at $13,244,000 after purchasing an additional 42,170 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Artivion by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company’s stock valued at $10,241,000 after buying an additional 8,343 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.